Commitments and Contingencies	6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies Intellectual Property License In August 2016, the Company and D.E. Shaw Research, LLC (“D.E. Shaw Research”) entered into the Collaboration and License Agreement, which was most recently amended in 2023 (“DESRES Agreement”). During the three and six months ended June 30, 2023 and 2022, there were no material changes to the DESRES Agreement. Accordingly, there were no changes to the Company’s accounting treatment thereon through June 30, 2023. The Company assessed the milestones under the DESRES Agreement at June 30, 2023 and December 31, 2022, concluding no such milestone payments were due. During the three months ended June 30, 2023 and 2022, the Company recorded research and development expenses of $2.4 million and $2.3 million, respectively, under the DESRES Agreement. During the six months ended June 30, 2023 and 2022, the Company recorded research and development expenses of $4.8 million and $4.7 million, respectively, under the DESRES Agreement. As of June 30, 2023 and December 31, 2022, the Company had accrued expense and accounts payable balances of $0.1 million and $0, respectively, for D.E. Shaw Research on its condensed consolidated balance sheets. As of June 30, 2023 and December 31, 2022, the Company had prepaid balances of $0.2 million and $4.9 million, respectively, for D.E. Shaw Research on its condensed consolidated balance sheets. Other Arrangements The Company has certain other research and license arrangements and other collaborations with third parties, which provide the Company with specified research and/or development services.

Commitments and Contingencies

6 Months Ended

Jun. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

9. Commitments and Contingencies

Intellectual Property License

In August 2016, the Company and D.E. Shaw Research, LLC (“D.E. Shaw Research”) entered into the Collaboration and License Agreement, which was most recently amended in 2023 (“DESRES Agreement”). During the three and six months ended June 30, 2023 and 2022, there were no material changes to the DESRES Agreement. Accordingly, there were no changes to the Company’s accounting treatment thereon through June 30, 2023.

The Company assessed the milestones under the DESRES Agreement at June 30, 2023 and December 31, 2022, concluding no such milestone payments were due.

During the three months ended June 30, 2023 and 2022, the Company recorded research and development expenses of $2.4 million and $2.3 million, respectively, under the DESRES Agreement.

During the six months ended June 30, 2023 and 2022, the Company recorded research and development expenses of $4.8 million and $4.7 million, respectively, under the DESRES Agreement.

As of June 30, 2023 and December 31, 2022, the Company had accrued expense and accounts payable balances of $0.1 million and $0, respectively, for D.E. Shaw Research on its condensed consolidated balance sheets.

As of June 30, 2023 and December 31, 2022, the Company had prepaid balances of $0.2 million and $4.9 million, respectively, for D.E. Shaw Research on its condensed consolidated balance sheets.

Other Arrangements

The Company has certain other research and license arrangements and other collaborations with third parties, which provide the Company with specified research and/or development services.